Chronic Myelomonocytic Leukemia in Remission Recruiting Phase 2 Trials for Cefotaxime (DB00493)

IndicationStatusPhase
DBCOND0090912 (Chronic Myelomonocytic Leukemia in Remission)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs